TRCT
RAPP

Tower Research Capital (TRC)’s Rapport Therapeutics RAPP Stock Holding History

Tower Research Capital (TRC)’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Sell
2,976
-816
-22% -$30K ﹤0.01% 2020
2026
Q1 		$119K Buy
3,792
+3,362
+782% +$94.6K ﹤0.01% 2050
2025
Q4 		$13K Sell
430
-626
-59% -$17.3K ﹤0.01% 3432
2025
Q3 		$31.4K Sell
1,056
-1,044
-50% -$18.6K ﹤0.01% 2899
2025
Q2 		$23.9K Buy
2,100
+1,178
+128% +$12.5K ﹤0.01% 3578
2025
Q1 		$9.25K Buy
922
+181
+24% +$2.35K ﹤0.01% 3804
2024
Q4 		$13.1K Buy
741
+484
+188% +$10.7K ﹤0.01% 3554
2024
Q3 		$5.26K Buy
+257
New +$5.52K ﹤0.01% 4301

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Tower Research Capital (TRC)'s RAPP Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Rapport Therapeutics (RAPP) stake by 22% in Q2 2026, selling an estimated $30K and leaving 2,976 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Tower Research Capital (TRC) first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Tower Research Capital (TRC) held 2,976 shares of Rapport Therapeutics worth $124K as of Q2 2026.
  • Tower Research Capital (TRC) sold 816 Rapport Therapeutics shares in Q2 2026, an estimated $30K.
  • Rapport Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2020 holding.
  • Tower Research Capital (TRC) first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.